Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Arbaclofen Administered for the Treatment of Social Function in Children and Adolescents With Autism Spectrum Disorders

Trial Profile

A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Arbaclofen Administered for the Treatment of Social Function in Children and Adolescents With Autism Spectrum Disorders

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 30 May 2019

At a glance

  • Drugs Arbaclofen (Primary)
  • Indications Autistic disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 May 2019 Planned initiation date changed from 1 Oct 2018 to 1 Jun 2019.
    • 20 Sep 2018 Status changed from planning to not yet recruiting.
    • 07 May 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top